Company intelligence / Profile preview
Signal26 Biotherapeutics
Epalinges, Vaud, Switzerlandsignal26bio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Signal26’s anti–IL‑26 monoclonal antibody has demonstrated efficacy in blocking IL‑26 activity both in vitro and in vivo murine models. The antibody has been humanized, with preclinical success reported. The company is preparing for first-in-human studies targeting pustular psoriasis, specifically PPPP.
- Therapeutic areas
- DermatologyImmunology
- Modalities
- Monoclonal antibodies (mAbs)Biological drugs/biologics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaboration with CHUV (Centre Hospitalier Universitaire Vaudois), Switzerland’s leading university hospital/research institution.
Beyond the preview
Go deeper on Signal26 Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Signal26 Biotherapeutics.